ICS-283: a system for targeted intravenous delivery of siRNA.
ICS-283 was developed within Intradigm Corporation as a system that is designed for the systemic delivery of therapeutic small interfering (siRNA) to sites of pathological angiogenesis. The non-viral siRNA delivery system is based on synthetic nanoparticles, known as Targe (Intradigm Corporation), which functions as a broad-platform technology to deliver siRNA to specific target cells in diseased tissues. The system is constructed to incorporate different functionalities that address critical needs for successful nucleic acid delivery. The TargeTran synthetic vector is a self-assembling, layered nanoparticle that protects and targets siRNA to specific cell types in pathological tissues. At present, ICS-283 is the only antiangiogenic siRNA delivery system that is designed for intravenous administration to treat angiogenesis-driven diseases.
Schiffelers
Raymond M
RM
Department of Pharmaceutics, Room Z735A, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB, Utrecht, The Netherlands. r.m.Schiffelers@pharm.uu.nl
Storm
Gert
G
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D051379:Mice; D049329:Nanostructures / Q000737:chemistry; D009389:Neovascularization, Pathologic / Q000628:therapy; D009842:Oligopeptides / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry; D011094:Polyethyleneimine / Q000737:chemistry; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics
D009842:Oligopeptides; D034741:RNA, Small Interfering; D011092:Polyethylene Glycols; C047981:arginyl-glycyl-aspartic acid; D011094:Polyethyleneimine; D040301:Vascular Endothelial Growth Factor Receptor-2